Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Integra LifeSciences Holdings Corporation IART

Healthcare — Medical Devices
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.10
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
13.92%

Capital & Financial Ratios

Market Cap
1,180.00
Revenue
1,647.67
Net Income
(7.24)
Free Cash Flow
25.80
Net Debt
1,554.62
Current Ratio
3.60
Debt/Equity
1.75
P/E ratio
0.00
P/S ratio
0.71
P/B ratio
1.13
Past 5Y EPS Growth
3.10%
This Y EPS Growth
10.17%
Next Y EPS Growth
6.18%
Next 5Y EPS Growth
8.53%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 309.10 273.57 263.74 274.08
Receivables 259.33 272.37 278.85 267.19
Inventory 389.61 429.09 492.74 492.01
Other 32.64 29.65 28.13 53.86
1,058.04 1,081.68 1,159.54 1,191.48
2023 2024 2025 Q'26
Payables 92.33 82.50 95.73 82.64
ST’ Debt — 573.17 87.80 —
Other 8.54 10.48 11.46 11.70
306.98 922.13 455.98 330.88
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 391.92 418.76 — —
—
’25 382.65 415.61 402.06 434.93
1,635.25
’24 368.87 418.18 380.83 442.65
1,610.53
’23 380.85 381.27 382.42 397.04
1,541.57
’22 376.64 397.82 385.19 398.02
1,557.67
’21 360.07 389.99 386.86 405.52
1,542.45
’20 354.32 258.67 370.23 388.65
1,371.87
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 9.80 22.80 — —
—
’25 (11.26) 8.92 40.91 11.82
50.38
’24 15.76 40.40 22.49 50.74
129.38
’23 26.16 28.28 26.77 58.75
139.96
’22 44.34 66.48 68.31 85.33
264.47
’21 69.08 91.29 82.78 69.28
312.43
’20 20.81 33.12 69.64 80.26
203.83
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (5.04) 10.50 — —
—
’25 (40.18) (11.23) 25.75 (19.60)
(45.25)
’24 0.29 10.69 (7.16) 11.19
15.01
’23 12.45 12.73 13.69 34.22
73.09
’22 35.02 57.07 59.16 82.02
233.27
’21 62.41 84.66 75.50 41.85
264.41
’20 4.33 29.17 62.92 72.18
168.60
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.06) 0.06 — —
—
’25 (0.33) (6.31) (0.07) (0.02)
(6.74)
’24 (0.04) (0.16) (0.14) 0.25
(0.09)
’23 0.29 0.05 0.24 0.25
0.84
’22 0.39 0.54 0.60 0.63
2.16
’21 0.53 0.41 0.51 0.53
1.98
’20 0.11 0.00 0.38 1.09
1.57

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.8
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 40.67 33.44 16.81 10.87 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 69.90 60.69 45.42 27.13 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,722 3,946 4,396 4,427 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.42 0.39 0.37 0.37 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,557.67 1,541.57 1,610.53 1,635.25 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 62.29% 57.39% 54.77% 50.86% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 213.89 81.07 (18.24) (563.50) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.73% 5.26% (1.13%) (34.46%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 180.55 67.74 (6.94) (516.47) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 125.14 129.68 146.49 157.44 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.77 19.25 20.91 21.33 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 2.16 0.84 (0.09) (6.74) ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.19 1.75 1.68 0.66 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.38) (0.83) (1.49) (1.25) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.81 0.91 0.19 (0.59) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.74 19.83 20.07 13.61 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 83.00 80.09 77.01 76.67 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.79 52.11 0.00 0.00 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.97 2.25 1.08 0.58 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.56 2.18 1.13 0.91 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.61 3.06 2.01 1.53 ‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.11 64.52 129.88 (80.70) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 264.47 139.96 129.38 50.38 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (31.20) (66.86) (114.37) (95.64) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 233.27 73.09 15.01 (45.25) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 840.59 751.06 159.56 703.56 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,458.19 1,485.02 1,769.19 1,817.36 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,001.53 1,175.92 1,495.62 1,553.62 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,804.40 1,587.88 1,545.28 1,043.46 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.71% 1.77% (0.18%) (13.52%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.32% 2.52% 0.58% (11.87%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.35% 3.99% (0.44%) (39.90%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Integra LifeSciences Holdings (IART) presents a compelling undervalued opportunity in medtech, with robust revenue growth—up 57% cumulatively from $992 million in 2016 to $1.55 billion in 2022, stabilizing at $1.54-$1.61 billion recently—overshadowed by short-term recalls of the Codman ICS+ shunt, which inflicted $100+ million in charges and drove 2024 to a slim $6.9 million net loss (-$0.09 EPS). Despite gross margins eroding to 54.8% and ROE dipping to -0.4%, the company’s revenue per employee remains efficient at ~$366k, and projections signal acceleration: revenue to $1.73 billion by 2027 (13% CAGR), with revenue per share surging 67% to $22.26 amid share reductions.

Balance sheet resilience shines through $1.55 billion equity (+84% since 2016) and positive FCF ($0.19/share in 2024), even as net debt hit $1.50 billion from acquisitions. Valuation screams discount: PS at 1.08x, PB at 1.13x, EV/Sales at 2.0x versus 1.3x forward, decoupling from steady top-line momentum—shares down 75% from 2021 highs of ~77 despite revenue per share gains.

Analyst forecasts ignite optimism: EPS rebounding from -$6.22 in 2025 to $1.47 by 2027, ROE to 16.7%, margins to 60%+, bolstered by insider buys (e.g., $102k director purchase), post-recall clearances, and tailwinds in regenerative tech. Targets imply 15-120% upside, echoing historical 50%+ rallies post-dips—positioning IART as a coiled spring for patient investors.

Read full commentary →

Integra LifeSciences Holdings Corporation (IART) Latest News

News by impact score

Fine-tune

10 Sep

3 , 10:25 AM
Analysis identifies three risks for Integra LifeSciences Holdings Corporation (IART) and recommends buying a different stock instead. Negative risk assessment may weigh on short-term investor sentiment and share price without altering core operations.

20 Aug

4 , 10:48 AM
Integra LifeSciences weighs SurgiMend relaunch as possible catalyst for broader company recovery by 2027. SurgiMend relaunch targets strategic product positioning that could materially shift Integra LifeSciences trajectory and investor outlook.

19 Aug

3 , 11:35 AM
Integra LifeSciences Holdings Corporation faces doubts on attractiveness as low valuation collides with execution risks. Valuation concerns paired with execution risks point to moderate influence on IART financial trajectory and investor views.

7 Aug

3 transcript www.fool.com, 9:03 PM
Integra LifeSciences Holdings Corporation held its Q2 2026 earnings call to discuss financial results and business outlook. Quarterly earnings call delivers performance updates and guidance that can shift near-term investor sentiment and valuation.

3 , 8:05 AM
Integra LifeSciences Holdings Corporation’s Q2 earnings call featured five analyst questions on operations, financial results, and strategic outlook. Analyst questions from the Q2 earnings call address key operational and market factors that can shape near-term investor views.

2 Aug

4 , 10:08 AM
Integra LifeSciences returned to profitability but trimmed its 2026 outlook. Trimming 2026 outlook after profitability signals risks to sustained growth and investor sentiment.

3 , 11:16 PM
Integra LifeSciences Holdings returns to profit while fair value debate remains active in the market. Profit recovery improves financial results for Integra LifeSciences but sustained fair value questions limit broader trajectory shifts.

1 Aug

3 , 12:43 PM
IART posted flat Q2 revenue with margin pressure and began operational realignment that now defines the company's outlook. Flat revenue and margin pressure from realignment are expected to affect near-term profitability and investor sentiment without fundamentally changing long-term trajectory.

29 Jul

4 , 6:00 AM
Integra LifeSciences Holdings Corporation reported its second quarter 2026 financial results. Quarterly financial results typically drive notable shifts in valuation and investor sentiment.

3 transcript app.moby.co, 1:35 PM
Integra LifeSciences Holdings Corporation conducted its Q2 2026 earnings call, covering quarterly financial results, operational updates, and forward-looking guidance for the company. Quarterly earnings calls typically provide financial metrics and guidance that moderately influence near-term stock performance and investor views.

3 www.marketbeat.com, 11:04 AM
Integra LifeSciences Q2 earnings call covered revenue, margins, segment performance, guidance updates and strategic priorities. Quarterly earnings and guidance directly shape near-term valuation and analyst views.

3 , 10:30 AM
Integra LifeSciences Holdings Corporation (IART) Q2 earnings include comparisons of key financial metrics against analyst estimates. Q2 earnings metrics versus estimates provide performance data that may moderately influence near-term investor sentiment and valuation.

24 Jul

3 , 9:05 AM
Integra LifeSciences Holdings Corporation encounters headwinds in the healthcare sector along with one other stock while a third shows promising prospects. Headwinds cited for Integra LifeSciences Holdings Corporation may pressure near-term operations and sentiment without altering long-term fundamentals.

18 Jul

3 , 2:08 AM
Integra LifeSciences Holdings (IART) earnings outperformance track record has transformed its investment story. Consistent earnings beats have shifted investor perceptions and trajectory for IART.

15 Jul

4 , 12:05 PM
IART stock surges 52.1% over the past year on positive drivers behind the rally. Major annual stock gains reflect strategic and operational factors capable of shifting company trajectory and sentiment.

27 Jun

3 , 6:09 AM
Integra LifeSciences implements new commercial structure that may alter investor perceptions of company execution and IART performance trajectory. New commercial structure introduces moderate operational changes that could influence execution and investor sentiment without fundamentally transforming company trajectory.

23 Jun

3 StockStory, 12:16 PM
Q1 results position Integra LifeSciences (NASDAQ:IART) within the surgical equipment and consumables specialty stocks peer group through direct benchmarking of financial and operational metrics. Q1 benchmarking against peers supplies moderate visibility into relative financial performance without indicating transformative strategic shifts.

18 May

3 Zacks, 9:50 AM
Integra LifeSciences (IART) is positioned as a top momentum stock for long-term investors due to strong performance metrics and favorable growth outlook. Positive momentum labeling can lift near-term investor sentiment and trading activity without altering core operations or fundamentals.

17 May

4 www.marketbeat.com, 6:02 PM
Integra LifeSciences reports transformation efforts succeeding ahead of SurgiMend relaunch. Transformation success claims plus imminent SurgiMend relaunch point to material revenue and positioning gains.

15 May

3 StockStory, 1:08 AM
Top 5 analyst questions from Integra LifeSciences Holdings Corporation (IART)'s Q1 earnings call highlight key investor concerns on performance, strategy, and outlook. Analyst questions from Q1 earnings call spotlight critical areas like financials and operations, moderately influencing investor sentiment and stock trajectory.

14 May

4 Simply Wall St., 1:17 PM
Integra LifeSciences (IART) shares rose 6.4% after Essig returned as CEO and reaffirmed 2026 guidance. CEO return and reaffirmed 2026 guidance triggered 6.4% stock surge, signaling significant leadership boost and sustained investor confidence.

9 May

4 Simply Wall St., 7:14 PM
Integra LifeSciences undergoes leadership changes and launches an ESOP initiative, spotlighting a significant gap between its market valuation and intrinsic worth. Leadership shift and ESOP move represent major strategic actions to address undervaluation and realign management incentives, likely influencing investor sentiment and long-term performance.

5 May

4 app.moby.co, 4:54 PM
Integra LifeSciences Holdings Corporation (IART) released its Q1 2026 earnings call summary, detailing quarterly financial performance, operational updates, and future outlook. Quarterly earnings call summaries reveal financial results and guidance that significantly shape investor expectations and stock trajectory.

4 transcript www.fool.com, 4:14 PM
Integra LifeSciences Holdings Corporation (IART) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward-looking guidance. Q1 2026 earnings call transcript reveals financial performance, strategic initiatives, and outlook that significantly influence stock price and investor expectations.

4 www.marketbeat.com, 3:27 PM
Integra LifeSciences Holdings Corporation (IART) released highlights from its Q1 earnings call, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights disclose key financial metrics, strategic updates, and guidance that significantly shape investor expectations and stock trajectory.

4 , 7:25 AM
Integra LifeSciences Holdings Corporation (IART) beat Q1 earnings and revenue estimates. Beating Q1 earnings and revenue estimates boosts investor sentiment and signals strong financial performance, significantly impacting market trajectory.

4 StockStory, 6:11 AM
Integra LifeSciences Holdings Corporation (NASDAQ:IART) exceeded Q1 CY2026 expectations. Beating quarterly expectations positively impacts financial performance and investor sentiment.

3 MT Newswires, 9:55 AM
Integra LifeSciences Holdings Corporation (IART) reported Q1 adjusted earnings and revenue increases, resulting in rising shares. Q1 adjusted earnings and revenue growth positively impacts financial performance and market sentiment without fundamentally altering long-term trajectory.

3 Zacks, 9:30 AM
Integra LifeSciences Holdings Corporation (IART) reported Q1 earnings, analyzing key metrics for performance insights. Q1 earnings reports moderately affect financial performance and investor sentiment through key metric analysis.

3 GlobeNewswire, 6:00 AM
Integra LifeSciences Holdings Corporation announced a leadership transition. Leadership transitions often moderately affect strategic direction, executive stability, and investor sentiment without fundamentally altering core operations.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us